NTRB

+ Watchlist + Portfolio

Nutriband Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.55
52-Week Range: $2.80 – $8.63
Market Cap: $46.38M
P/E (TTM): —
EPS (TTM): -2.56
Dividend Yield: —

Advanced Metrics

Price/Book: 7.74
PEG Ratio: —
Return on Equity: -145.72%
Return on Assets: -78.18%
Gross Margin: 28.36%
Operating Margin: -289.42%
Profit Margin: 0.00%
Current Ratio: 5.26
Debt/Equity: 0.04
Total Debt: $232.71K
Free Cash Flow: $-1.72M
Revenue Growth: -35.10%
Earnings Growth: —
Enterprise Value: $42.60M

NTRB Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$2.08M	$2.09M	$2.14M	$2.04M
Cost of Revenue	$1.33M	$1.22M	$1.40M	$1.47M
Gross Profit	$750.41K	$862.11K	$743.32K	$566.31K
Research & Development	$982.23K	$1.96M	$3.12M	$1.89M
Selling, General & Admin	$3.92M	$3.77M	$4.31M	$6.99M
Operating Expenses	$4.90M	$5.73M	$7.43M	$8.88M
Operating Income	-$4.15M	-$4.87M	-$6.69M	-$8.32M
EBITDA	-$4.15M	-$5.12M	-$10.18M	-$8.01M
Pretax Income	-$4.48M	-$5.49M	-$10.48M	-$8.23M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$4.48M	-$5.49M	-$10.48M	-$8.23M
Diluted EPS	-0.53	-0.69	-0.99	-2.58
Diluted Shares	8.46M	7.95M	10.61M	11.64M

NTRB Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$1.99M	$492.94K	$4.31M	$4.57M
Receivables	$113.05K	$148.65K	$73.85K	$118.40K
Inventory	$229.34K	$168.60K	$212.04K	$117.99K
Current Assets	$2.69M	$1.02M	$4.79M	$4.99M
Total Assets	$9.46M	$7.52M	$7.47M	$7.55M
Current Liabilities	$748.61K	$999.09K	$982.85K	$784.28K
Long-Term Debt	$100.50K	$79.83K	$58.20K	$35.86K
Total Debt	$185.81K	$241.28K	$186.35K	$245.49K
Total Liabilities	$883.39K	$1.08M	$1.04M	$868.45K
Retained Earnings	-$22.49M	-$27.98M	-$38.46M	-$46.69M
Shareholders' Equity	$8.57M	$6.44M	$6.43M	$6.68M
Working Capital	$1.95M	$22.77K	$3.81M	$4.20M

NTRB Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$2.99M	-$3.53M	-$4.63M	-$5.13M
Capital Expenditure	-$79.30K	-$51.76K	-$92.04K	-$5.32K
Free Cash Flow	-$3.07M	-$3.58M	-$4.72M	-$5.14M
Depreciation & Amortisation	$330.14K	$287.72K	$285.05K	$193.80K
Stock-Based Compensation	$732.13K	$742.70K	$1.54M	$2.74M
Investing Cash Flow	-$79.30K	-$51.76K	-$92.04K	-$5.32K
Financing Cash Flow	$160.07K	$2.09M	$8.54M	$5.40M
Share Repurchases	-$119.01K	$0.00	-$148.55K	$0.00
Net Change in Cash	-$2.91M	-$1.49M	$3.82M	$263.14K

NTRB Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$667.43K	$622.45K	$346.06K	$400.71K	$433.40K
Cost of Revenue	$415.45K	$465.57K	$277.55K	$311.77K	$236.60K
Gross Profit	$251.98K	$156.88K	$68.50K	$88.94K	$196.80K
Research & Development	$683.43K	$562.55K	$457.11K	$188.04K	$247.26K
Selling, General & Admin	$982.05K	$1.60M	$3.49M	$921.82K	$1.20M
Operating Expenses	$1.67M	$2.16M	$3.95M	$1.11M	$1.45M
Operating Income	-$1.41M	-$2.00M	-$3.88M	-$1.02M	-$1.25M
EBITDA	-$1.33M	-$1.94M	-$3.82M	-$926.85K	-$1.20M
Pretax Income	-$1.39M	-$2.00M	-$3.87M	-$968.06K	-$1.24M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$1.39M	-$2.00M	-$3.87M	-$968.06K	-$1.24M
Diluted EPS	-0.12	-2.12	-0.32	—	-0.10
Diluted Shares	11.13M	11.22M	12.06M	—	12.16M

NTRB Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$2.96M	$7.00M	$5.31M	$4.57M	$4.01M
Receivables	$94.14K	$160.80K	$147.56K	$118.40K	$2.63K
Inventory	$215.32K	$138.03K	$136.00K	$117.99K	$121.49K
Current Assets	$3.43M	$7.52M	$5.82M	$4.99M	$4.38M
Total Assets	$6.15M	$10.18M	$8.42M	$7.55M	$6.89M
Current Liabilities	$925.05K	$1.57M	$772.52K	$784.28K	$832.14K
Long-Term Debt	$52.63K	$47.29K	$41.60K	$35.86K	$29.82K
Total Debt	$282.44K	$270.35K	$258.02K	$245.49K	$232.71K
Total Liabilities	$1.05M	$1.68M	$870.21K	$868.45K	$902.31K
Retained Earnings	-$39.85M	-$41.85M	-$45.72M	-$46.69M	-$47.93M
Shareholders' Equity	$5.10M	$8.49M	$7.55M	$6.68M	$5.99M
Working Capital	$2.50M	$5.95M	$5.04M	$4.20M	$3.54M

NTRB Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.34M	-$1.31M	-$1.75M	-$731.83K	-$563.10K
Capital Expenditure	-$5.32K	—	—	—	—
Free Cash Flow	-$1.34M	-$1.31M	-$1.75M	-$731.83K	-$563.10K
Depreciation & Amortisation	$57.48K	$57.38K	$43.06K	$35.88K	$34.18K
Stock-Based Compensation	$63.35K	$41.05K	$2.54M	$98.51K	$552.46K
Investing Cash Flow	-$5.32K	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	-$5.32K	$5.34M	$69.56K	-$5.49K	-$5.57K
Share Repurchases	$0.00	—	—	—	—
Net Change in Cash	-$1.35M	$4.03M	-$1.68M	-$737.32K	-$568.67K

Market Snapshot

About

Nutriband develops and commercializes transdermal pharmaceutical and over-the-counter products using proprietary abuse-deterrent and controlled-release drug delivery technologies. The company focuses on creating safer, more effective topical delivery systems for pain management, smoking cessation, and other therapeutic applications through its AVERSA technology platform.